Dr. Craig Woods, a research veterinarian and BioVeteria’s General Manager, stated “BioVeteria chose to establish their headquarters in Arizona for several reasons, including Arizona’s strong comparative antivenom research programs such as University of Arizona’s Viper Institute. In addition, Arizona represents the epicenter for venomous snakebites in pets, therefore giving our team the ability to directly assist in treating dogs.”

BioVeteria Life Sciences, LLC conducts a significant portion of their R&D in Arizona at various labs and veterinary specialty hospitals. Dr. Woods stated, “Veterinarians treat about 25 times more venomous snakebites compared to physicians, so the veterinary market need for antivenom is substantial. I have seen first hand the significant benefit of this new antivenom for dogs, and am excited to be part of such a needed program from veterinary medicine.” It is estimated that hundreds of thousands of dogs are bitten by rattlesnakes, cottonmouths, and other pit vipers in the United States each year. Many of these dogs require antivenom to avoid severe complications or death. Currently, there is only one approved antivenom for veterinary medicine so the market opportunity for additional antivenoms is substantial.